Artificial intelligence (AI)-assisted training improves pathologist accuracy in human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) scoring in patients with breast cancer.

Discover which therapies are expected to grab the HER2-low cancers market share @ HER2-low Cancers Market Report The HER2-low ...

Breast cancers with low HER2 expression can be difficult to identify using immunohistochemistry or in situ hybridization. Approximately one in three HER2-ultralow breast cancers will be initially ...

In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 ...

The analysis was performed on independent study sets of HER2-positive and negative/low breast cancers, already analyzed by central immunohistochemistry (IHC) and FISH testing. Phospho-HER2 and ...

The ORR was 52.4% and the median PFS was 6.6 months in patients with HER2 IHC 0. The ORR reached 72.2% and the median PFS was 9.4 months in patients with HER2 expression (IHC 1+/2+/3+).

These include: ER-negative status Lower ER expression (≤70%) in ER+ tumors HER2 IHC of 3+ (vs. IHC 2+/ISH+) Use of weekly paclitaxel rather than every-3-week docetaxel Higher HER2DX pCR score ...